These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 39369320)

  • 1. Double Hit in Clear-Cell Renal Cell Carcinoma With Germline Pathogenic ATM Mutation and Somatic VHL Mutation.
    Chan KH; Clavijo ND; Ayala G; Hall R; Wray C; Cen P
    J Investig Med High Impact Case Rep; 2024; 12():23247096241286370. PubMed ID: 39369320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Rare Case of Synchronous Fumarate Hydratase-Deficient Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma With Fumarate Hydratase and von Hippel-Lindau Gene Mutations: A Clinicopathologic and Molecular Study.
    Wen H; Zheng L; Zhang M; Pan X; Wang D; Qian J; Zhang X; Zhou Q; Chen N
    Int J Surg Pathol; 2024 Jun; 32(4):810-816. PubMed ID: 37715637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenic ATM and BAP1 germline mutations in a case of early-onset, familial sarcomatoid renal cancer.
    Bell HN; Kumar-Sinha C; Mannan R; Zakalik D; Zhang Y; Mehra R; Jagtap D; Dhanasekaran SM; Vaishampayan U
    Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report.
    Ferlicot S; Just PA; Compérat E; Rouleau E; Tissier F; Vaessen C; Richard S
    Diagn Pathol; 2021 Nov; 16(1):107. PubMed ID: 34801057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
    Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
    Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
    Vlachostergios PJ; Papathanassiou M; Anagnostou M; Thodou E; Tamposis I; Mitrakas L; Zachos I; Koukoulis GK; Samara M; Tzortzis V
    F1000Res; 2023; 12():918. PubMed ID: 38933491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.
    van Houwelingen KP; van Dijk BA; Hulsbergen-van de Kaa CA; Schouten LJ; Gorissen HJ; Schalken JA; van den Brandt PA; Oosterwijk E
    BMC Cancer; 2005 Jun; 5():57. PubMed ID: 15932632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three novel germ-line VHL mutations in Hungarian von Hippel-Lindau patients, including a nonsense mutation in a fifteen-year-old boy with renal cell carcinoma.
    Losonczy G; Fazakas F; Pfliegler G; Komáromi I; Balázs E; Pénzes K; Berta A
    BMC Med Genet; 2013 Jan; 14():3. PubMed ID: 23298237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development.
    Clifford SC; Walsh S; Hewson K; Green EK; Brinke A; Green PM; Gianelli F; Eng C; Maher ER
    Genes Chromosomes Cancer; 1999 Sep; 26(1):20-8. PubMed ID: 10441001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family.
    Yuan P; Sun Q; Liang H; Wang W; Li L; Wang Y; Deng H; Lai L; Chen X; Zhou X
    Cancer Biol Ther; 2016 Jun; 17(6):599-603. PubMed ID: 27057652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3.
    Malinoc A; Sullivan M; Wiech T; Schmid KW; Jilg C; Straeter J; Deger S; Hoffmann MM; Bosse A; Rasp G; Eng C; Neumann HP
    Endocr Relat Cancer; 2012 Jun; 19(3):283-90. PubMed ID: 22351710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the hereditary background of renal cancer in Denmark.
    Christensen MB; Wadt K; Jensen UB; Lautrup CK; Bojesen A; Krogh LN; Overeem Hansen TV; Gerdes AM
    PLoS One; 2019; 14(4):e0215725. PubMed ID: 31034483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
    Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
    PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study.
    Schouten LJ; van Dijk BA; Oosterwijk E; Hulsbergen-van de Kaa CA; Kiemeney LA; Goldbohm RA; Schalken JA; van den Brandt PA
    J Hypertens; 2005 Nov; 23(11):1997-2004. PubMed ID: 16208141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
    Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
    Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.
    Jilg CA; Neumann HP; Gläsker S; Schäfer O; Ardelt PU; Schwardt M; Schultze-Seemann W
    Urol Int; 2012; 88(1):71-8. PubMed ID: 22156657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.
    Carlo MI; Mukherjee S; Mandelker D; Vijai J; Kemel Y; Zhang L; Knezevic A; Patil S; Ceyhan-Birsoy O; Huang KC; Redzematovic A; Coskey DT; Stewart C; Pradhan N; Arnold AG; Hakimi AA; Chen YB; Coleman JA; Hyman DM; Ladanyi M; Cadoo KA; Walsh MF; Stadler ZK; Lee CH; Feldman DR; Voss MH; Robson M; Motzer RJ; Offit K
    JAMA Oncol; 2018 Sep; 4(9):1228-1235. PubMed ID: 29978187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel VHL targets that are associated with the development of renal cell carcinoma.
    Abdulrahman M; Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Wiesener MS; Richards FM; Johnson CM; Latif F; Maher ER
    Oncogene; 2007 Mar; 26(11):1661-72. PubMed ID: 17001320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC.
    Gallou C; Joly D; Méjean A; Staroz F; Martin N; Tarlet G; Orfanelli MT; Bouvier R; Droz D; Chrétien Y; Maréchal JM; Richard S; Junien C; Béroud C
    Hum Mutat; 1999; 13(6):464-75. PubMed ID: 10408776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.